Loading...
The 2024 American Society of Clinical Oncology (ASCO) annual meeting, held May 30 to June 3 in Chicago, highlighted important advances in treatment across a broad spectrum of malignancies. Here, NEJM Journal Watch Oncology and Hematology Associate Editor Robert Dreicer, MD, MS, MACP, FASCO, reviews key trials in GU cancers.
In patients with locally advanced or metastatic urothelial cancer, treatment with enfortumab vedotin improves progression-free survival (PFS) and overall survival (OS) at all levels of exposure, compared with chemotherapy, according to an industry-supported pharmacokinetics analysis.
Researchers examined data from the EV-101, EV-201…